News and Announcements
Prescient Therapeutics Share Purchase Plan Results
- Published November 18, 2015 3:48PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th November 2015, ASX Announcement
Cancer drug development Prescient Therapeutics Limited (ASX: PTX) has closed its Share Purchase Plan, with strong demand from existing and new investors.
Investors have subscribed for $1,201,500 in new shares, with the price per share to be based on a 20% discount to the 5 day volume weighted average price (VWAP) before the issue date of 23 November 2015.
A final price will be announced on the date of issue of the SPP shares.
PTX advises that the Company is only permitted to accept a maximum of 30% of its current issued capital. In the event that a scale back is required, applications are new shares will be scaled back proportionately
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
